

MOMETASONE / OLOPATADINE nasal spray (Ryaltris®) for allergic rhinitis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of MOMETASONE / OLOPATADINE nasal spray (Ryaltris®) for allergic rhinitis.

GREY

Mometasone / olopatadine nasal spray (Ryaltris®) is indicated in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.^[1]

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, treatment of allergic rhinitis should continue to follow national guidance, local pathways, and local formulary choices.

- > NICE Clinical Knowledge Summary: [Allergic rhinitis](#) (revised August 2021)
- > NICE Pathway: [Nose conditions](#) (updated 20 August 2021)
- > Pan Mersey APC Formulary: [12.02.01 Drugs used in nasal allergy](#)

References

1. Glenmark Pharmaceuticals Europe Ltd. Summary of Product Characteristics; [Ryaltris 25 micrograms/actuation + 600 micrograms/actuation Nasal Spray, suspension](#), 11 May 2021. Accessed online 25 November 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.